GENFIT S.A EBITDA 2019-2021 | GNFT
GENFIT S.A ebitda from 2019 to 2021. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
| GENFIT S.A Annual EBITDA (Millions of US $) |
|
|---|---|
| 2021 | $38 |
| 2020 | $-91 |
| 2019 | $-64 |
| 2018 | $-80 |
| GENFIT S.A Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2021-12-31 | |
| 2020-12-31 | |
| 2020-06-30 | |
| 2019-12-31 | |
| 2019-06-30 | |
| 2018-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $0.172B | $0.101B |
| Genfit SA is a biopharmaceutical company. It focuses on the discovery and development of therapeutic and diagnostic solutions in metabolic and liver related diseases. The company's lead products include Elafibranor, Nitazoxanide and TGFTX1 which are in clinical stage. Genfit SA is based in Loos, France. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $164.215B | 9.99 |
| Bio-Rad Laboratories (BIO.B) | United States | $15.121B | 32.79 |
| QIAGEN (QGEN) | Netherlands | $10.343B | 16.33 |
| Biohaven Pharmaceutical Holding (BHVN) | United States | $10.057B | 0.00 |
| Ginkgo Bioworks Holdings (DNA) | United States | $4.540B | 0.00 |
| Emergent Biosolutions (EBS) | United States | $1.675B | 7.17 |
| Arcus Biosciences (RCUS) | United States | $1.287B | 32.64 |
| Myovant Sciences (MYOV) | United Kingdom | $0.927B | 0.00 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.486B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.347B | 0.00 |
| Zymeworks (ZYME) | Canada | $0.336B | 0.00 |
| Ambrx Biopharma (AMAM) | United States | $0.154B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.113B | 23.10 |
| SQZ Biotechnologies (SQZ) | United States | $0.094B | 0.00 |
